Arterial Hypertension, Diabetes Mellitus, Heart Failure, Lymphoproliferative Disease, Total Knee Replacement
Conditions
Keywords
heart failure, diabetes mellitus, arterial hypertension, lymphoproliferative diseases, knee replacement, remote monitoring, mHealth, telemedicine, voice assistant
Brief summary
DIALOG is a study to assess the efficacy and safety of remote patient monitoring using virtual operator voice technologies and a business intelligence (BI) system for timely detection, prevention of early complications, worsening of the condition, and other adverse events in patients who have been discharged from the hospital.
Detailed description
After ensuring that the patient's characteristics meet the inclusion and exclusion criteria and confirming the patient's ability to use the "voice assistant", as provided in the research protocol, patients who have completed the briefing will be able to use the voice assistant at home. During the month, robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system will be conducted for five groups of patients (CHF, DM, AH, LPD, and patients who underwent total knee replacement) who have been discharged from the hospital. The system developed allows for quick surveys, collection of data on patient conditions, and convenient transfer of this data to the physician. The physician will receive information on patient status in a graphical form using a traffic light system. In the event of any red flags, the physician will contact the patient for further discussion on treatment strategies. The study will evaluate the efficacy and safety of utilizing the "voice assistant" by assessing the achievement of target values for controlled parameters, evaluating patient satisfaction and adherence to treatment, reducing the number of repeat hospitalization, and reducing overall mortality and cardiovascular-related mortality.
Interventions
DEVICEVoice assistant
Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease. Follow-up and management of disease provided by specialists at participating institutions.
Sponsors
PJSC VimpelCom
I.M. Sechenov First Moscow State Medical University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Disease diagnosed according to the latest Clinical practice guidelines * Stable condition at the time of discharge from the hospital * Written informed consent to participate in the study Non-inclusion criteria: * Diagnosed dementia or severe cognitive impairment * The inability to use automatic devices to register blood pressure at home, a blood glucose meter * Alcohol or drug abuse * Inability to contact a voice assistant and other study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and/or comply with the protocol instructions or follow-up procedures
Exclusion criteria
* Unwillingness of the patient to continue participating in the study * The development of conditions related to the criteria of non-inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cardiovascular mortality | an average, 1 month after randomization | mortality rate |
| all-cause mortality | an average, 1 months after randomization | mortality rate |
| complications, decompensations | an average, 1 month after randomization | rate of complications and exacerbations of the main disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| achievement target or maximally tolerated doses | an average, 1 month after randomization | achievement target or maximally tolerated doses for CHF, DM and AH |
| satisfaction | an average, 1 month after randomization | satisfaction of patients and doctors with the robotic speech questionnaire |
| changes in medical adherence | an average, 1 month after randomization | change in amount of taking drugs and doses |
Countries
Russia
Contacts
Primary ContactMaria Kozhevnikova, Professor
Backup ContactAleksei Emelianov, Assistant
Outcome results
None listed